A decade ago, Mark Pruzanski was running Intercept Pharmaceuticals Inc. alone out of his West Village apartment and was $100,000 in debt. At one point, the company had $4.41 in its checking account. . By last Friday, the 45-person firm was the hottest company in the biotechnology sector, its market capitalization having soared more than sixfold over the course of one week, to $8.6 billion from $1.4 billion, after its liver-disease drug performed surprisingly well in a clinical trial funded by the National Institutes of Health....
  